| Literature DB >> 31699025 |
Xiaoling Yu1, Wen Zhang2, Zhiping Zhao1, Chengsong Ye3, Shuyan Zhou4, Shaogui Wu4, Lifen Han1, Zhaofang Han5,6, Hanhui Ye7.
Abstract
BACKGROUND: The enhancing incidence of carbapenem-resistant Klebsiella pneumoniae (CRKP)-mediated infections in Mengchao Hepatobiliary Hospital of Fujian Medical University in 2017 is the motivation behind this investigation to study gene phenotypes and resistance-associated genes of emergence regarding the CRKP strains. In current study, seven inpatients are enrolled in the hospital with complete treatments. The carbapenem-resistant K. pneumoniae whole genome is sequenced using MiSeq short-read and Oxford Nanopore long-read sequencing technology. Prophages are identified to assess genetic diversity within CRKP genomes.Entities:
Keywords: Carbapenem-resistant; Klebsiella pneumoniae; Whole-genome sequencing; bla KPC-2
Mesh:
Substances:
Year: 2019 PMID: 31699025 PMCID: PMC6839148 DOI: 10.1186/s12864-019-6225-9
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Antibiotic susceptibility profiles of K. pneumoniae. The results of antimicrobial susceptibility testing - antibiotics MIC (mg/L) and breakpoint interpretation or epidemiological cut-off value
| Isolates | 1566D | 1567D | 2035D | 2036D | 2037D | 2038D | 2039D | 2040D |
|---|---|---|---|---|---|---|---|---|
| source | sputum | bile | sputum | sputum | blood | sputum | sputum | environment |
| Infection | Pulmonary | Abdominal | Pulmonary | Pulmonary | Pulmonary | Pulmonary | Pulmonary | N/A |
| ampicillin | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) |
| ampicillin/sulbactam | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) |
| piperacillin/tazobactam | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) |
| cefazolin | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
| cefotetan | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
| ceftazidime | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
| ceftriaxone | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
| cefepime | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
| aztreonam | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
| imipenem | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) |
| amikacin | ≥64(R) | ≤4(S) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
| gentamicin | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) |
| tobramycin | ≥16(R) | ≤2(S) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) |
| ciprofloxacin | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) |
| levofloxacin | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) |
| macrodantin | 256(R) | 256(R) | ≥512(R) | ≥512(R) | ≥512(R) | ≥512(R) | ≥512(R) | ≥512(R) |
| sulfamethoxazole/trimethoprim | ≥320(R) | ≤20(S) | ≤20(S) | ≤20(S) | ≤20(S) | ≥320(R) | ≥320(R) | ≥320(R) |
S susceptible, I intermediate, R resistant
Assembly statistics of seven CRKP strains via short-read sequencing
| Assembly | 1566D | 2035D | 2036D | 2037D | 2038D | 2039D | 2040D |
|---|---|---|---|---|---|---|---|
| Contig number | 195 | 163 | 215 | 242 | 184 | 196 | 195 |
| Total length (bp) | 5,758,754 | 5,633,502 | 5,432,179 | 5,670,795 | 5,833,697 | 5,831,354 | 5,835,044 |
| Largest contig (bp) | 380,781 | 381,132 | 929,110 | 380,795 | 381,132 | 381,056 | 381,056 |
| GC (%) | 57.33 | 57.39 | 57.18 | 57.35 | 57.21 | 57.21 | 57.2 |
| N50 | 176,606 | 196,479 | 251,620 | 196,479 | 183,862 | 190,289 | 183,862 |
| L50 | 12 | 11 | 7 | 11 | 11 | 11 | 11 |
| Total number of Ns | 20 | 30 | 20 | 30 | 130 | 130 | 30 |
Fig. 1Intact prophages identified in eight CRKP strains
Resistance genes among the patient and environmental isolates
| Isolates | 1566D | 2035D | 2036D | 2037D | 2038D | 2039D | 2040D |
|---|---|---|---|---|---|---|---|
| MLST | ST11 | ST11 | ST2632 | ST11 | ST11 | ST11 | ST11 |
| pMLST | IncF[F33:A-:B-] | IncF[F33:A-:B-] | IncHI1, IncF | IncF[F33:A-:B-] | IncF[F33:A-:B-] | IncF[F33:A-:B-] | IncF[F33:A-:B-] |
| Plasmids | IncR, ColRNAI | IncR, ColRNAI | IncR, ColRNAI | IncR, ColRNAI | IncR, ColRNAI | IncR, ColRNAI | IncR, ColRNAI |
| Penicillins: Ampicillin/ Narrow-Spectrum Cephalosporins: cefazolin and cefotetan | |||||||
| β-lactam inhibitors/ Carbapenems | |||||||
| Extended-Spectrum Cephalosporins/ Monobactam | |||||||
| Aminoglycosides | |||||||
| Fluoroquinolones | |||||||
| Phosphonic Acid | |||||||
| Phenicol | – | ||||||
| Folate-pathway Inhibitors |
Fig. 2Assessing the genetic relatedness of the CRKP by WGS. a Clustering of all isolates based on sequence similarity. b Communal SNP markers detected by pairwise comparison analysis
Fig. 3Genome-wide association study (GWAS) results of the eight CRKP strains